Bayer Pharma Aktiengesellschaft

Lead Discovery Center Gmbh

John Harris

Wilfried Schwab

Zoltán Greff

Bert Klebl

Axel Choidas

Edmund Hoppe

Joelle Le

Jackie Macritchie

Don Simpson

Gerhard Müller

Klaus Godl

Doris Hafenbradl

Brad Sherborne

Vladimir Savic

Jose Bravo

Birgit Zech

Andrea Missio

Peter Habenberger

Thomas Herget

Christian Hartung

Achim Freisleben

Beatrice Felber

Ola Engkvist

Matt Cotten

Alexander Backes

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Growing community of inventors

Eynsford, United Kingdom

John Harris